Innate Pharma annual r&d spending
2017
2018
2019
2020
2021
2022
2023
2024
2025
Innate Pharma R&D Spending Growth & History (IPH)
Innate Pharma's r&d spending was €43.6M for fiscal 2025.
View full Innate Pharma company overviewInnate Pharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €43.6M | −€8.4M | −16.08% |
| 2024 | 2024-12-31 | €52.0M | −€4.0M | −7.22% |
| 2023 | 2023-12-31 | €56.0M | €4.4M | +8.44% |
| 2022 | 2022-12-31 | €51.7M | €4.7M | +9.91% |
| 2021 | 2021-12-31 | €47.0M | −€2.7M | −5.44% |
| 2020 | 2020-12-31 | €49.7M | −€29.1M | −36.95% |
| 2019 | 2019-12-31 | €78.8M | €9.3M | +13.35% |
| 2018 | 2018-12-31 | €69.6M | €2.6M | +3.81% |
| 2017 | 2017-12-31 | €67.0M | — | — |
Innate Pharma r&d spending trends
Over the last five fiscal years, Innate Pharma's r&d spending decreased from €49.7M to €43.6M, a change of −€6.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Innate Pharma source filings ↗